As hematopoletic stem cells collected from peripheral blood are increasingly used for autologous and allogeneic stem cell transplantation, new approaches for the mobilization of stem cells are needed. These should have the goal of improving stem cell collection and reducing the duration and toxicity of the mobilization process. AMD3100, a specific inhibitor of CXCR4, one of the key molecules that tethers hematopoietic stem cells to the bone marrow microenvironment, is a promising new agent currently in clinical development for autologous and allogeneic stem cell mobilization. Early clinical trials have demonstrated that AMD3100 rapidly mobilizes stem cells to the peripheral blood, with minimal side effects. In Phase II trials, mobilization with the combination of AMD3100 and granulocyte colony-stimulating factor (G-CSF) results in the collection of more progenitor cells than G-CSF alone.

Original languageEnglish
Pages (from-to)19-27
Number of pages9
JournalFuture Oncology
Issue number1
StatePublished - Feb 1 2007


  • AMD3100
  • Multiple myeloma
  • Non-Hodgkin lymphoma
  • Stem cell mobilization
  • Stem cell transplantation


Dive into the research topics of 'AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent'. Together they form a unique fingerprint.

Cite this